Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Research (NASDAQ:ARWR) and Biomerica Inc (NASDAQ:BMRA).
Arrowhead Research (ARWR)
In a report issued on August 31, Madhu Kumar from B.Riley FBR reiterated a Hold rating on Arrowhead Research, with a price target of $18. The company’s shares opened today at $14.60.
Kumar observed:
“This morning, 8/31, Arrowhead Pharmaceuticals (ARWR) announced the completion of dosing in the Phase I trial of α-1 antitrypsin (AAT) RNAi drug ARO-AAT for AAT PiZZ liver disease. While we consider this a positive event for ARWR shares, we look forward to presentation of Phase I trial results likely at the Diseases (AASLD) San Francisco. We thus reiterate our ARWR Neutral rating and $18 price target, and remind investors that Arrowhead Pharmaceuticals will be participating at the B. Riley FBR York City.”
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 32.7% and a 66.7% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Deciphera Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Research with a $20.08 average price target.
See today’s analyst top recommended stocks >>
Biomerica Inc (BMRA)
In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Biomerica Inc, with a price target of $7.50. The company’s shares opened today at $3.60, close to its 52-week low of $2.62.
D’silva commented:
“Biomerica, Inc. (BMRA) filed its 10-K for FY18 (FYE: May ) AMC on 8/29 and its earnings PR was released BMO, 8/30. The company does not host earnings calls. BMRA’s F4Q18 top-line/EPS/ adj. EBITDA came in at $1.1M/($0.08)/($0.6)M, compared to our estimate of $1.5M/($0.06)/ ($0.5)M—we represent consensus. The top- and bottom-line shortfall was primarily due to weaker sales out of Asia than we modeled for, and the company also highlighted that the quarter was impacted by delays related to the launch of a colorectal screening program at a drug store chain. We continue to believe new partnerships and BMRA’s product pipeline position the enterprise for growth and share price appreciation in the coming years.”
According to TipRanks.com, D’silva is a 5-star analyst with an average return of 31.6% and a 58.3% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Oramed Pharmaceuticals, and Sorrento Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Biomerica Inc.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
